These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25375908)

  • 1. Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
    Maccari R; Ottanà R
    J Med Chem; 2015 Mar; 58(5):2047-67. PubMed ID: 25375908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of aldose reductase inhibitors for the treatment of inflammatory disorders.
    Chatzopoulou M; Pegklidou K; Papastavrou N; Demopoulos VJ
    Expert Opin Drug Discov; 2013 Nov; 8(11):1365-80. PubMed ID: 24090200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications.
    Kovacikova L; Prnova MS; Majekova M; Bohac A; Karasu C; Stefek M
    Molecules; 2021 May; 26(10):. PubMed ID: 34066081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CADD Studies in the Discovery of Potential ARI (Aldose Reductase Inhibitors) Agents for the Treatment of Diabetic Complications.
    Gupta SK; Tripathi PK
    Curr Diabetes Rev; 2023; 19(9):e180822207672. PubMed ID: 35993470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential use of aldose reductase inhibitors to prevent diabetic complications.
    Zenon GJ; Abobo CV; Carter BL; Ball DW
    Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
    Giannoukakis N
    Expert Opin Investig Drugs; 2008 Apr; 17(4):575-81. PubMed ID: 18363521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of aldose reductase inhibitors in diabetic complications: recent trends.
    Kaul CL; Ramarao P
    Methods Find Exp Clin Pharmacol; 2001 Oct; 23(8):465-75. PubMed ID: 11838322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
    Kador PF; Wyman M; Oates PJ
    Prog Retin Eye Res; 2016 Sep; 54():1-29. PubMed ID: 27102270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase inhibitors and nanodelivery of diabetic therapeutics.
    Prior AM; Thapa M; Hua DH
    Mini Rev Med Chem; 2012 Apr; 12(4):326-36. PubMed ID: 22303947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research progress in aldose reductase].
    Gu J; Yan J; Wu W; Huang Q; Ouyang D
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 35(4):395-400. PubMed ID: 20448367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose reductase inhibitors: 2013-present.
    Quattrini L; La Motta C
    Expert Opin Ther Pat; 2019 Mar; 29(3):199-213. PubMed ID: 30760060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel aldose reductase inhibitors: a patent survey (2006--present).
    Chatzopoulou M; Alexiou P; Kotsampasakou E; Demopoulos VJ
    Expert Opin Ther Pat; 2012 Nov; 22(11):1303-23. PubMed ID: 22998509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of chronic microvascular complications of diabetes mellitus with aldose reductase inhibitors].
    Wajchenberg BL
    Rev Assoc Med Bras (1992); 1996; 42(2):63-5. PubMed ID: 9110450
    [No Abstract]   [Full Text] [Related]  

  • 15. Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.
    Kousaxidis A; Petrou A; Lavrentaki V; Fesatidou M; Nicolaou I; Geronikaki A
    Eur J Med Chem; 2020 Dec; 207():112742. PubMed ID: 32871344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions.
    Sonowal H; Ramana KV
    Curr Med Chem; 2021; 28(19):3683-3712. PubMed ID: 33109031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospecting for novel plant-derived molecules of Rauvolfia serpentina as inhibitors of Aldose Reductase, a potent drug target for diabetes and its complications.
    Pathania S; Randhawa V; Bagler G
    PLoS One; 2013; 8(4):e61327. PubMed ID: 23613832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic and molecular docking studies of loganin and 7-O-galloyl-D-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase.
    Lee CM; Jung HA; Oh SH; Park CH; Tanaka T; Yokozawa T; Choi JS
    Arch Pharm Res; 2015 Jun; 38(6):1090-8. PubMed ID: 25315636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.
    Yabe-Nishimura C
    Pharmacol Rev; 1998 Mar; 50(1):21-33. PubMed ID: 9549756
    [No Abstract]   [Full Text] [Related]  

  • 20. Aldose reductase inhibitors.
    Kirchain WR; Rendell MS
    Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.